Rate My Professor Christopher Parris

Parris teaches courses in cell and molecular biology, biology, genetics, and cancer treatment. He has supervised ten PhD students as first supervisor and four postdoctoral research fellows. Notable grants under his principal investigatorship include determining the mechanism of action of a therapeutic antibody targeting annexin pathways (Oncobiopharm Ltd, £123,000, 2018-19), the role of the tumour suppressor gene BAP1 in uveal melanoma (The Bart’s Charity, £180,000, 2016-18), construction of a library of cells defective in DNA double strand break repair (The Bart’s Charity, £105,000, 2015-16), and development of DNA repair biomarkers for predicting chemotherapy and radiotherapy responses (The Bart’s Charity, £277,000, 2013-17). Selected publications are 'The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells' (Journal of Cancer, 2017), 'Lentivirus-mediated frataxin gene delivery reverses genome instability in Friedreich ataxia patient and mouse model fibroblasts' (Gene Therapy, 2016), and 'Enhanced γ-H2AX DNA damage foci detection using multimagnification and extended depth of field in imaging flow cytometry' (Cytometry Part A, 2015). A member of the Association for Radiation Research (UK), Parris has featured in a BBC Breakfast television interview on novel genes involved in human melanoma skin cancer.